Immatics (IMTX) News Today → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free IMTX Stock Alerts $10.47 +0.05 (+0.48%) (As of 09:53 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineImmatics (NASDAQ:IMTX) Short Interest Updateamericanbankingnews.com - April 16 at 5:34 AMImmatics (NASDAQ:IMTX) Stock Price Up 5.4%marketbeat.com - April 1 at 5:50 PMMaintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnershipsmarkets.businessinsider.com - March 29 at 2:59 PMImmatics (NASDAQ:IMTX) Stock Price Down 3.7%marketbeat.com - March 28 at 8:24 PMImmatics (NASDAQ:IMTX) Shares Gap Down to $12.05marketbeat.com - March 21 at 3:15 PMIMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 21 at 3:03 PMImmatics Announces Full Year 2023 Financial Results and Corporate Updateglobenewswire.com - March 21 at 7:00 AMImmatics (NASDAQ:IMTX) Sees Strong Trading Volumemarketbeat.com - March 19 at 11:54 AMWellington Management Group LLP Cuts Holdings in Immatics (NASDAQ:IMTX)marketbeat.com - March 19 at 4:54 AMImmatics (IMTX) to Release Quarterly Earnings on Tuesdaymarketbeat.com - March 18 at 7:39 AMWith 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big gunsfinance.yahoo.com - March 15 at 8:05 AMAdage Capital Partners GP L.L.C. Invests $3.78 Million in Immatics (NASDAQ:IMTX)marketbeat.com - March 11 at 6:42 AMCantor sees strong year ahead for oncology M&Aseekingalpha.com - March 10 at 2:31 PMCantor Fitzgerald sees strong year ahead for oncology M&Amsn.com - March 10 at 2:31 PMBuy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic Partnershipsmarkets.businessinsider.com - March 7 at 1:05 PMImmatics (NASDAQ:IMTX) Sets New 12-Month High at $13.16marketbeat.com - March 1 at 12:15 PMImmatics (NASDAQ:IMTX) Stock Holdings Lowered by 683 Capital Management LLCmarketbeat.com - March 1 at 10:35 AMEditas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watchseekingalpha.com - February 28 at 8:03 PMBolton TV star to 'go back to Fernandos one last time' as he spreads the loveuk.yahoo.com - February 6 at 5:05 AMImmatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last yearfinance.yahoo.com - February 3 at 1:12 PMImmatics: Pioneering TCR Therapies In The Fight Against Cancerseekingalpha.com - February 3 at 7:56 AMTD Asset Management Inc Buys 100,200 Shares of Immatics (NASDAQ:IMTX)marketbeat.com - January 20 at 5:23 AMImmatics commences public offering of sharesmsn.com - January 17 at 9:13 PMImmatics Announces Pricing of $175 Million Public Offeringfinance.yahoo.com - January 17 at 9:13 PMImmatics Announces Proposed Public Offeringfinance.yahoo.com - January 17 at 4:13 PMShort Interest in Immatics (NASDAQ:IMTX) Expands By 36.5%marketbeat.com - January 15 at 8:57 PMPositive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh’s Recommendationmarkets.businessinsider.com - November 20 at 6:58 PMImmatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming Catalystsmarkets.businessinsider.com - November 16 at 10:03 PMImmatics Announces Third Quarter 2023 Financial Results and Business Updatemarkets.businessinsider.com - November 14 at 8:29 AMImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trialfinanznachrichten.de - November 8 at 7:35 AMImmatics (IMTX) Moves 23.2% Higher: Will This Strength Last?finance.yahoo.com - November 6 at 1:10 PMCantor Fitzgerald Initiates Coverage of Immatics N.V (IMTX) with Overweight Recommendationnasdaq.com - November 3 at 6:04 AMImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapyfinance.yahoo.com - October 24 at 7:27 AMDown -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)msn.com - October 12 at 3:25 PMAnalyzing Immatics' Multi-Faceted Investment Caseseekingalpha.com - October 9 at 1:33 AMIMTX Oct 2023 10.000 putfinance.yahoo.com - September 21 at 3:52 PMQ3 2023 EPS Estimates for Immatics Increased by Leerink Partnrs (NASDAQ:IMTX)marketbeat.com - September 21 at 7:40 AMImmatics shares rise on Moderna cancer collaborationmarketwatch.com - September 11 at 4:22 PMModerna enters cancer collaboration with Immatics worth $1.8Bbizjournals.com - September 11 at 4:22 PMImmatics (NASDAQ:IMTX) Shares Purchased by Wellington Management Group LLPmarketbeat.com - September 7 at 6:09 AMThose who invested in Immatics (NASDAQ:IMTX) three years ago are up 27%finance.yahoo.com - August 27 at 4:24 PMHow Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%msn.com - August 21 at 5:37 PMAnalysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), CVS Health (CVS)markets.businessinsider.com - August 18 at 9:51 AMMizuho Securities Keeps Their Buy Rating on Immatics (IMTX)markets.businessinsider.com - August 18 at 9:51 AMImmatics GAAP EPS of -€0.32, revenue of €22.4Mmsn.com - August 17 at 6:50 PMChardan Capital Sticks to Their Buy Rating for Immatics (IMTX)markets.businessinsider.com - August 17 at 6:50 PMImmatics Announces Second Quarter 2023 Financial Results and Business Updatefinance.yahoo.com - August 17 at 7:21 AMJump Financial LLC Reduces Stock Holdings in Immatics (NASDAQ:IMTX)marketbeat.com - August 14 at 4:44 AMImmatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumorsfinance.yahoo.com - August 10 at 10:33 AMImmatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203seekingalpha.com - July 24 at 7:52 PM Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… IMTX Media Mentions By Week IMTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMTX News Sentiment▼-1.000.44▲Average Medical News Sentiment IMTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMTX Articles This Week▼11▲IMTX Articles Average Week Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Relay Therapeutics News Today REGENXBIO News Today BioCryst Pharmaceuticals News Today CARGO Therapeutics News Today Cabaletta Bio News Today Kyverna Therapeutics News Today Cullinan Oncology News Today Adaptimmune Therapeutics News Today Scholar Rock News Today HilleVax News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMTX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
